CRBP has 36-month beta value of 3.12. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRBP is 10.72M, and currently, short sellers hold a 17.60% ratio of that float. The average trading volume of CRBP on June 04, 2025 was 171.95K shares.
CRBP) stock’s latest price update
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP)’s stock price has gone rise by 13.08 in comparison to its previous close of 7.34, however, the company has experienced a 12.77% increase in its stock price over the last five trading days. zacks.com reported 2025-05-23 that NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
CRBP’s Market Performance
Corbus Pharmaceuticals Holdings Inc (CRBP) has seen a 12.77% rise in stock performance for the week, with a 6.55% gain in the past month and a 22.60% surge in the past quarter. The volatility ratio for the week is 6.81%, and the volatility levels for the past 30 days are at 6.22% for CRBP. The simple moving average for the past 20 days is 14.93% for CRBP’s stock, with a -51.54% simple moving average for the past 200 days.
Analysts’ Opinion of CRBP
Wedbush gave a rating of “Outperform” to CRBP, setting the target price at $85 in the report published on July 30th of the previous year.
CRBP Trading at 24.75% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.59% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Jenkins John Kenneth, who sale 2,783 shares at the price of $7.35 back on May 30 ’25. After this action, Jenkins John Kenneth now owns 33 shares of Corbus Pharmaceuticals Holdings Inc, valued at $20,465 using the latest closing price.
Altmeyer Anne, the Director of Corbus Pharmaceuticals Holdings Inc, sale 1,392 shares at $7.25 during a trade that took place back on May 30 ’25, which means that Altmeyer Anne is holding 1,391 shares at $10,096 based on the most recent closing price.
Stock Fundamentals for CRBP
The total capital return value is set at -0.46. Equity return is now at value -44.89, with -37.86 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.6. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.99.
Currently, EBITDA for the company is -37.74 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.82.
Conclusion
To put it simply, Corbus Pharmaceuticals Holdings Inc (CRBP) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
